MX2022007623A - Combinaciones. - Google Patents
Combinaciones.Info
- Publication number
- MX2022007623A MX2022007623A MX2022007623A MX2022007623A MX2022007623A MX 2022007623 A MX2022007623 A MX 2022007623A MX 2022007623 A MX2022007623 A MX 2022007623A MX 2022007623 A MX2022007623 A MX 2022007623A MX 2022007623 A MX2022007623 A MX 2022007623A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- disease
- treating
- compounds
- condition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
- Glass Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952032P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/065410 WO2021127045A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007623A true MX2022007623A (es) | 2022-09-23 |
Family
ID=76478077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007623A MX2022007623A (es) | 2019-12-20 | 2020-12-16 | Combinaciones. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230054854A1 (enExample) |
| EP (1) | EP4069242A4 (enExample) |
| JP (1) | JP7750526B2 (enExample) |
| KR (1) | KR20220119420A (enExample) |
| CN (2) | CN121102230A (enExample) |
| AU (1) | AU2020404996A1 (enExample) |
| BR (1) | BR112022012283A2 (enExample) |
| CA (1) | CA3165474A1 (enExample) |
| IL (1) | IL294094A (enExample) |
| MX (1) | MX2022007623A (enExample) |
| TW (1) | TWI875898B (enExample) |
| WO (1) | WO2021127045A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102124715B1 (ko) * | 2015-11-03 | 2020-06-18 | 제넨테크, 인크. | 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물 |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| KR20200108301A (ko) * | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| WO2019165204A1 (en) * | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
| US12220415B2 (en) * | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2020
- 2020-12-16 AU AU2020404996A patent/AU2020404996A1/en active Pending
- 2020-12-16 KR KR1020227024701A patent/KR20220119420A/ko active Pending
- 2020-12-16 IL IL294094A patent/IL294094A/en unknown
- 2020-12-16 BR BR112022012283A patent/BR112022012283A2/pt unknown
- 2020-12-16 CN CN202511346658.2A patent/CN121102230A/zh active Pending
- 2020-12-16 US US17/757,530 patent/US20230054854A1/en active Pending
- 2020-12-16 WO PCT/US2020/065410 patent/WO2021127045A1/en not_active Ceased
- 2020-12-16 JP JP2022538232A patent/JP7750526B2/ja active Active
- 2020-12-16 MX MX2022007623A patent/MX2022007623A/es unknown
- 2020-12-16 CA CA3165474A patent/CA3165474A1/en active Pending
- 2020-12-16 EP EP20904098.9A patent/EP4069242A4/en active Pending
- 2020-12-16 CN CN202080095323.7A patent/CN115135325B/zh active Active
- 2020-12-18 TW TW109145167A patent/TWI875898B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202135819A (zh) | 2021-10-01 |
| CN115135325A (zh) | 2022-09-30 |
| BR112022012283A2 (pt) | 2022-08-30 |
| WO2021127045A1 (en) | 2021-06-24 |
| CN115135325B (zh) | 2026-04-03 |
| AU2020404996A1 (en) | 2022-07-14 |
| EP4069242A4 (en) | 2024-01-10 |
| CA3165474A1 (en) | 2021-06-24 |
| CN121102230A (zh) | 2025-12-12 |
| NZ790037A (en) | 2025-08-29 |
| US20230054854A1 (en) | 2023-02-23 |
| JP2023508332A (ja) | 2023-03-02 |
| EP4069242A1 (en) | 2022-10-12 |
| IL294094A (en) | 2022-08-01 |
| KR20220119420A (ko) | 2022-08-29 |
| TWI875898B (zh) | 2025-03-11 |
| JP7750526B2 (ja) | 2025-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007623A (es) | Combinaciones. | |
| CO2020000527A2 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| MX2022007629A (es) | Combinaciones. | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CO2022002637A2 (es) | Proceso de fabricación de moduladores de cftr | |
| CL2021001228A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CO2020013840A2 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
| MX2022007626A (es) | Combinaciones. | |
| MX2017013801A (es) | Métodos para tratar el cáncer. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX2022014131A (es) | Monoterapias y terapias de combinacion. | |
| MX2022007628A (es) | Combinaciones. | |
| MX2020004179A (es) | Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso. | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa |